Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly and Company and Nimbus Therapeutics today announced a research collaboration and exclusive worldwide license agreement to develop and commercialize…
Lilly's deal with Nimbus Therapeutics is a $496 million bet on AMP-activated protein kinase activation, a metabolic mechanism that has produced more pipeline…
Nimbus and Lilly announced a new research collaboration and exclusive worldwide license for a novel oral obesity treatment, with Nimbus eligible for…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Nimbus Therapeutics entered a research collaboration and exclusive worldwide license with Eli Lilly to develop and commercialize selective AMPK isoform activators for metabolic diseases. Total deal payments could reach up to $496M plus tiered mid-single to low-double-digit royalties on net sales. Nimbus leads research; Lilly leads development and commercialization. Post-deal development: on February 25, 2025 Nimbus announced it had achieved a research milestone in the collaboration with the discovery of a highly selective isoform-specific AMPK activator, described as solving a decades-old AMPK selectivity challenge (preclinical). The collaboration remained active; in January 2026 Lilly and Nimbus signed a separate, larger ($1.3B potential) oral-obesity collaboration that explicitly built on this 2022 AMPK pact.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Nimbus Therapeutics LLC (this deal) | 2022 | $496M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2022 deals · Eli Lilly and Company deals · Metabolic deals